EUVIMEDEUVIMED entdecken
Crossref

Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: A prospective cohort spanning sequential treatment lines

Maya Fischman, Lihi Godny, Adi Friedenberg, Revital Barkan, Ian White, Nir Wasserberg, Keren Rabinowitz, Irit Avni-Biron, Hagar Banai, Yifat Snir, Yelena Broitman, Maor H Pauker und 3 weitere

Digestive and Liver Disease · 2025

DOI: 10.1016/j.dld.2025.10.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Maya Fischman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel. Electronic address: fischmaya@gmail.com. Hauptthemen laut MEDLINE: Pouchitis, Gastrointestinal Agents, Colonic Pouches, Proctocolectomy, Restorative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Leona M and Harry B Helmsley Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic inflammation of the pouch may affect a significant proportion of patients following ileal pouch-anal anastomosis (IPAA), increasingly treated by advanced therapies. Persistence of such agents or evidence to guide sequencing is scarce. This study aims to quantify first- and advanced-line drug persistence and identify factors associated with discontinuation. METHODS: This single-center prospective cohort enrolled adults with IPAA (1986-2021) who initiated biologic/small-molecule therapy between 2001-2024. Persistence was defined as treatment continuation at the last follow-up. Kaplan-Meier and Cox models estimated persistence and its predictors. RESULTS: Of 186 patients, 38 (20.4 %) initiated advanced therapy. Overall follow-up was 16.8y. Agents included: adalimumab 21 (32 %), infliximab 17 (26 %), ustekinumab 16 (25 %), vedolizumab 5 (7.7 %), upadacitinib 3 (4.6 %), risankizumab 1 (1.5 %), certolizumab 1 (1.5 %), and golimumab 1 (1.5 %). Advanced treatment commenced at a median of 10.7y after ileostomy closure. Advanced treatments (≥2nd line) were prescribed for 15 patients (40 %). Each additional treatment line doubled the discontinuation risk (HR 2.48, 95 % CI 1.26-4.90). Ustekinumab retained the highest persistence post-failure of a previous advanced therapy. CONCLUSIONS: In inflammatory pouch disorders, biologic/small-molecule persistence falls steeply after first-line failure, underscoring the importance of early drug selection and avoidance of recycled pre-IPAA agents. Ustekinumab shows superior persistence both as first- and second-line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PouchitisGastrointestinal AgentsColonic PouchesProctocolectomy, RestorativeHumansFemaleMaleProspective StudiesAdultMiddle AgedChronic DiseaseUstekinumabKaplan-Meier EstimateProportional Hazards ModelsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Antibiotic refractory pouchitisBiologicsChronic pouchitisPouchitis

Substanzen

Gastrointestinal AgentsUstekinumabvedolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel. Electronic address: fischmaya@gmail.com.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Surgery, Rabin Medical Center, Petah-Tikva, Israel.
  • Felsenstein Medical Research Center, Rabin Medical Center, and Tel Aviv University, Israel.
  • Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.

Förderung

  • Leona M and Harry B Helmsley Charitable Trust

Zitieren

APA

Fischman, M., Godny, L., Friedenberg, A., Barkan, R., White, I., Wasserberg, N., Rabinowitz, K., Avni-Biron, I., Banai, H., Snir, Y., Broitman, Y., Pauker, M. H., Yanai, H., Dotan, I., & Ollech, J. E. (2025). Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: A prospective cohort spanning sequential treatment lines. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.10.028

Vancouver

Fischman M, Godny L, Friedenberg A, Barkan R, White I, Wasserberg N, et al. Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: A prospective cohort spanning sequential treatment lines. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.10.028

BibTeX
@article{Fischman2025,
  author = {Fischman, Maya and Godny, Lihi and Friedenberg, Adi and Barkan, Revital and White, Ian and Wasserberg, Nir and Rabinowitz, Keren and Avni-Biron, Irit and Banai, Hagar and Snir, Yifat and Broitman, Yelena and Pauker, Maor H and Yanai, Henit and Dotan, Iris and Ollech, Jacob E},
  title = {Drug persistence of first- and advanced-line therapy for chronic inflammatory pouch disorders: A prospective cohort spanning sequential treatment lines},
  journal = {Digestive and Liver Disease},
  year = {2025},
  doi = {10.1016/j.dld.2025.10.028}
}
Kostenlos starten →